Intravenous tirofiban with intra-arterial urokinase and mechanical thrombolysis in stroke: Preliminary experience in 11 cases

Stroke

Volumn 36, Issue 10, 2005, Pages 2154-2158

  Mangiafico, Salvatore ^a   Cellerini, Martino ^a,c   Nencini, Patrizia ^b   Gensini, Gianfranco ^b   Inzitari, Domenico ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Centro Traumatologico Ortopedico   (Italy)

Author keywords

Endovascular therapy; Platelet glycoprotein GPIIb IIIa complex; Stroke

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN; UROKINASE;

ADULT; AGED; ANGIOGRAPHY; ANGIOPLASTY; ARTICLE; BASILAR ARTERY; BLEEDING; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; BOLUS INJECTION; BRAIN HEMORRHAGE; CATHETER; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GUIDE WIRE; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTERNAL CAROTID ARTERY OCCLUSION; LUNG EMBOLISM; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RANKIN SCALE; RECANALIZATION; RISK ASSESSMENT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BALLOON DILATATION; CAROTID STENOSIS; CATHETERIZATION; CEREBROVASCULAR ACCIDENT; COMBINED MODALITY THERAPY; FEMALE; HEPARIN; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; RISK; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME; TYROSINE; URINARY PLASMINOGEN ACTIVATOR;

EID: 26444543280     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000181751.06736.64     Document Type: Article

References (23)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59:862-867.
3. Trouillas P, Nighoghossian N, Getenet JC, Riche G, Neuschwander P, Froment JC, Turjman F, Jin JX, Malicier D, Fournier G, Gabry AL, Ledoux X, Derex L, Berthezène Y, Adeleine P, Xie J, French P, Dechevanne M. Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke. Correlations of outcome with clinical and radiological data. Stroke. 1996;27:882-890.
4. Del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998;29:4-11.
5. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. J Am Med Assoc. 1999;282:2003-2011.
6. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
7. Straub S, Junghans U, Jovanovic V, Wittsack HJ, Seitz RJ, Siebler M. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke. 2004;35:705-709.
8. Lee DH, Jo KD, Kim HG, Choi SJ, Jung SM, Ryu DS, Park MS. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. J Vasc Interv Radiol. 2002;13:769-723.
9. Eckert B, Koch C, Thomalla G, Roether J, Zeumer H. Acute basilar artery occlusion treated with combined intravenous abciximab and intra-arterial tissue plasminogen activator, report of 3 cases. Stroke. 2002;33:1424-1427.
10. Cloft HJ, Samuels OB, Tong FC, Dion JE. Use of abciximab for mediation of thromboembolic complications of endovascular therapy. AJNR Am J Neuroradiol. 2001;22:1764-1767.
11. Lempert TE, Malek AM, Halbach VV, Phatouros CC, Dowd CF, Higashida RT. Rescue treatment of acute parent vessel thrombosis with glycoprotein IIb/IIIa inhibitor during GDC coil embolization. Stroke. 1999;30:693-695.
12. Wallace RC, Furlan AJ, Moliterno DJ, Stevens GH, Masaryk TJ, Perl J II. Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor. AJNR Am J Neuroradiol. 1997;18:1257-1260.
13. Rebello SS, Driscoll EM, Lucchesi BR. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist prevents rethrombosis after successful thrombolysis in the dog. Stroke. 1997;28:1789-1796.
14. Abumiya T, Fitridge R, Mazur C, Copeland BR, Koziol JA, Tschopp JF, Pierschbacher MD, Del Zoppo GJ. Integrin alfa(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral schemia. Stroke. 2000;31:1402-1410.
15. Barber PA, Demehuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet. 2000;355:1670-1674.
16. Fassbender K, Dempfle CE, Mielke O, Schwartz A, Daffertshofer M, Eschenfelder C, Dollman M, Hennerici M. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke. 1999;30:2101-2104.
17. Siess W. Molecular mechanisms of platelet activation. Physiol Rev. 1989;69:58-178.
18. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation. 1998;97:544-552.
19. Junghans U, Seitz RJ, Aulich A, Freund HJ, Siebler M. Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study. Cerebrovasc Dis. 2001;12:308-312.
20. Ueda T, Sakaki S, Nochide I, Kumon Y, Kohno K, Ohta S. Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries Stroke. 1998;29:2568-2574.
21. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-1453.
22. de Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KA, Palmisano J, Ramsey KE, Bilheimer DW, Lewis EF, Pfeffer M, Califf RM, Braunwald E; A to Z investigators. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy. Results from the A phase of the A-to-Z trial. Eur Heart J. 2004;25:1688-1694.
23. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J. 2000;139:S38-S45.